People: Endo International PLC (ENDP.OQ)

ENDP.OQ on NASDAQ Stock Exchange Global Select Market

7 Aug 2020
Change (% chg)

$-0.15 (-4.24%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Coleman, Blaise 

Mr. Blaise Coleman has been appointed as President, Chief Executive Officer, Director of the Company effective 3/6/2020. Mr. Coleman was serving as Endo's Interim Chief Financial Officer since November 22, 2016. Mr. Coleman joined Endo in January 2015 as Vice President of Corporate Financial Planning & Analysis and was promoted to Senior Vice President of Global Finance Operations in November 2015. Prior to joining Endo, Mr. Coleman held a number of finance leadership roles with AstraZeneca, a global biopharmaceutical company, latterly as the Chief Financial Officer of the AstraZeneca/Bristol-Myers Squibb US Diabetes Alliance from January 2013 until January 2015. Prior to this, he was the Head of Finance for the AstraZeneca Global Medicines Development organization based in Mölndal, Sweden from September 2011 to January 2013. Mr. Coleman joined AstraZeneca as Senior Director Commercial Finance for the US Cardiovascular Business in November 2007. He joined AstraZeneca from Centocor, a wholly owned subsidiary of Johnson & Johnson, where he held positions in the respective Licenses & Acquisitions and Commercial Finance organizations. Mr. Coleman’s move to Centocor in early 2003 followed 7 years’ experience with the global public accounting firm, PricewaterhouseCoopers LLP. He is a Certified Public Accountant. Mr. Coleman received a Bachelor of Science in accounting from Widener University and a MBA from Duke University, The Fuqua School of Business.

Basic Compensation

Total Annual Compensation, USD 1,877,220
Restricted Stock Award, USD 1,672,730
Long-Term Incentive Plans, USD --
All Other, USD 21,701
Fiscal Year Total, USD 3,571,650

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --